(DNLI) – Company Press Releases
-
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences
-
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
-
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
-
Denali Therapeutics Announces $500 million Private Placement Equity Financing
-
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
-
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
-
DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING
-
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
-
Flagship Pioneering and Samsung Announce Collaboration to Advance Groundbreaking Technologies in Translational Science and Medicine
-
Flagship Pioneering Debuts Enabling Technologies Initiative
-
Sail Biomedicines Provides Update on Research with Cystic Fibrosis Foundation and Pioneering Medicines
-
Thermo Fisher Scientific & Flagship Pioneering Expand Ongoing Strategic Partnership to Jointly Create New Platform Companies with First-in-Class Enabling Technologies for Life Sciences
-
Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders
-
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
-
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
-
Flagship Pioneering Launches Pioneering Intelligence
-
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines
-
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics
-
Flagship Pioneering Named to Fortune's 2023 "Change the World" List
-
ProFound Therapeutics Expands Leadership Team With Appointment of Klaus Urbahns as Chief Scientific Officer
-
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
-
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
-
Invaio achieves first registration for citrus greening solution featuring Trecise™ technology
-
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner
-
Alltrna Expands Leadership Team with Appointments of Chief Scientific Officer and Chief Technology Officer
-
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines
-
Alltrna Announces Series B Raise of $109 Million to Advance tRNA Medicines for Stop Codon Disease
-
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
-
Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs
-
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
-
Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons
-
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
-
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
-
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
-
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
-
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
-
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
-
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
-
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
-
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
-
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
-
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
-
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
-
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
-
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
-
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
-
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
-
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
-
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
-
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
Back to DNLI Stock Lookup
